Loading…
Natera, Inc. is projected to rise to $334.95 by 2027, a +33% move from its current price of $252.22. NTRA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $247.01 | $252.31 | $257.74 | +0.04% |
| Aug 1 | $244.93 | $252.41 | $260.11 | +0.07% |
| Aug 2 | $243.37 | $252.50 | $261.98 | +0.11% |
| Aug 3 | $242.08 | $252.60 | $263.57 | +0.15% |
| Aug 4 | $240.96 | $252.69 | $265.00 | +0.19% |
| Aug 5 | $239.96 | $252.79 | $266.30 | +0.22% |
| Aug 6 | $239.05 | $252.88 | $267.51 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $239.05 | $252.88 | $267.51 | +0.26% |
| Week 2 | $234.15 | $253.54 | $274.54 | +0.52% |
| Week 3 | $230.61 | $254.21 | $280.22 | +0.79% |
| Week 4 | $227.75 | $254.87 | $285.23 | +1.05% |
| Week 5 | $225.33 | $255.54 | $289.80 | +1.32% |
| Week 6 | $223.23 | $256.21 | $294.06 | +1.58% |
| Week 7 | $221.36 | $256.88 | $298.11 | +1.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Natera, Inc. is a diagnostics company that engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, Latitude, a blood-based MRD test for colorectal cancer, Altera, a tissue-based comprehensive genomic profiling test, and Empower, a hereditary cancer screening test.
The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT; and Vistara, a single-gene NIPT. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; and Renasight, a kidney gene panel test. It also provides Constellation software, a cloud-based distribution model, NateraCore platform, phlebotomy services, and EMR integration services.
The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use.
The company also collaborates with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. Natera was founded in 2003 and is headquartered in Austin, Texas, and was formerly known as Gene Security Network, LLC before changing its name to Natera, Inc.
in January 2012.
Natera, Inc. (NTRA) is a diagnostics company with a broad molecular testing portfolio and global reach. Its stock is listed with a current price of $258.03 and a market cap of $36.95B, and it ranks 363 by market capitalization.
The long-run price outlook is bullish, with the forecast showing higher average prices in coming years—2030 average $678.14 and 2050 average $4,984.81—alongside substantial upside potential. In addition, the forecast indicates meaningful ROIs in later years (e.g., 162.8% in 2030, 693.1% in 2040, and 1831.9% in 2050). The near term begins with a neutral reading for 2026, reflecting an average price of $258.03.
A major floor 28.8% below — a decisive break under it would weaken the trend.
The nearest floor, 15.9% below — buyers have tended to step in here.
The nearest ceiling, 12.5% above — a clean break opens room to run.
A major ceiling 28.1% above — clearing it would confirm fresh momentum.
Key NTRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NTRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $263.22 | Sell | $262.60 | Sell |
| MA 10 | $267.00 | Sell | $265.27 | Sell |
| MA 20 | $271.67 | Sell | $263.26 | Sell |
| MA 50 | $239.29 | Buy | $246.79 | Buy |
| MA 100 | $220.36 | Buy | $231.83 | Buy |
| MA 200 | $218.79 | Buy | $215.72 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.94 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -164.24 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -3.88 | Sell |
| ROC (12) | -8.45 | Sell |
| Bollinger %B (20,2) | 0.01 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.60 | Buy |
| Awesome (5,34) | 8.55 | Buy |
| Ultimate (7,14,28) | 33.56 | Neutral |
| Momentum (10) | -14.86 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 260.19 | Sell |
| ADX (14) | 21.89 | Sell |
| ATR (14) | 4.70 | Info |
The 30-day technical picture is bullish.
Key metrics show RSI14 at 50, with a SMA50 of $237.96 and a SMA200 of $218.32. Support is noted at $212.07 and resistance at $283.80. The 30-day price range spans from a low of $224.28 to a high of $296.85.
Annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $182.65 | $252.22 | $324.36 | 0% | Neutral | |
| $272.44 | $334.95 | $431.88 | +33% | Bullish | |
| $329.49 | $413.86 | $549.96 | +64% | Bullish | |
| $420.60 | $537.70 | $731.60 | +113% | Bullish | |
| $510.52 | $662.79 | $919.95 | +163% | Bullish | |
| $539.64 | $710.46 | $1,003.46 | +182% | Bullish | |
| $614.63 | $819.73 | $1,176.10 | +225% | Bullish | |
| $698.90 | $943.45 | $1,373.03 | +274% | Bullish | |
| $740.07 | $1,010.50 | $1,490.05 | +301% | Bullish | |
| $898.96 | $1,240.90 | $1,852.29 | +392% | Bullish | |
| $1,381.24 | $2,002.03 | $3,146.43 | +694% | Bullish | |
| $3,097.82 | $4,873.19 | $8,262.88 | +18.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $182.65 | $252.22 | $294.82 | +0.00% |
| August 2026 | $216.30 | $252.80 | $301.58 | +0.23% |
| September 2026 | $221.87 | $260.96 | $314.53 | +3.23% |
| October 2026 | $225.41 | $266.48 | $323.83 | +2.12% |
| November 2026 | $221.49 | $262.96 | $321.68 | -1.32% |
| December 2026 | $221.12 | $263.54 | $324.36 | +0.22% |
Click any year to see its month-by-month NTRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NTRA could reach as high as $324.36, with a base case around $252.22 and support toward $182.65 — roughly 0% from $252.22. Price action looks broadly range-bound.
Expect NTRA to range from $272.44 to $431.88 through 2027. The $334.95 average target implies a +33% move from current prices. That is up +33% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The NTRA price prediction for 2028 points to an average of $413.86 (low $329.49, high $549.96) — a potential gain of +64% on today's $252.22. Momentum favours further upside here.
In 2029, NTRA is projected to trade between $420.60 and $731.60, averaging $537.70 — a potential gain of +113% from today's $252.22. That is up +30% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Natera, Inc.'s 2030 outlook centres on $662.79, within a $510.52 to $919.95 range. That is up +23% on the projected 2029 average. That marks a +163% change versus current levels. Momentum favours further upside here.
By 2031, NTRA could reach as high as $1,003.46, with a base case around $710.46 and support toward $539.64 — roughly +182% from $252.22. Buyers look set to stay in control over this stretch.
Expect NTRA to range from $614.63 to $1,176.10 through 2032. The $819.73 average target implies a +225% move from current prices. That is up +15% on the projected 2031 average. Momentum favours further upside here.
The NTRA price prediction for 2033 points to an average of $943.45 (low $698.90, high $1,373.03) — a potential gain of +274% on today's $252.22. Buyers look set to stay in control over this stretch.
In 2034, NTRA is projected to trade between $740.07 and $1,490.05, averaging $1,010.50 — a potential gain of +301% from today's $252.22. That is up +7% on the projected 2033 average. Momentum favours further upside here.
Natera, Inc.'s 2035 outlook centres on $1,240.90, within a $898.96 to $1,852.29 range. That is up +23% on the projected 2034 average. That marks a +392% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NTRA could reach as high as $3,146.43, with a base case around $2,002.03 and support toward $1,381.24 — roughly +694% from $252.22. Momentum favours further upside here.
Expect NTRA to range from $3,097.82 to $8,262.88 through 2050. The $4,873.19 average target implies a +18.3x move from current prices. That is up +143% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NTRA today (≈ 3.964793 NTRA) could be worth
$19,321.21
+$18,321.21 (+1832%) by 2050 · US Dollar
Based on the average projected NTRA price of $4,873.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NTRAwould be worth at today's price.
$1,000 invested in NTRA on Jul 28, 2025 (≈ 7.246377 NTRA) would be worth
$1,827.68
+$827.68 (+82.8%) today · 1.83× · US Dollar
Based on a NTRA entry price of $138 vs. today's $252.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $262.63 | $960.36 | -4.0% |
| 1 month ago | $261.91 | $963 | -3.7% |
| 3 months ago | $200.17 | $1,260.03 | +26.0% |
| 6 months ago | $235.93 | $1,069.05 | +6.9% |
| 1 year ago | $138 | $1,827.68 | +82.8% |
| All time (5.0y) ago | $112.33 | $2,245.35 | +124.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NTRA forecast.
Our base-case forecast reaches $500.00 around 2029.
Implied market cap at $500.00: $71.61B
The multi-year forecast points to a bullish trajectory across the horizon. The average price is projected at $258.03 for 2026, rising to $678.14 in 2030, then to $2,046.39 in 2040 and $4,984.81 in 2050.
Forecasted ROIs accompany these moves: 0% in 2026, 162.8% in 2030, 693.1% in 2040, and 1831.9% in 2050. Sentiment shifts from Neutral in 2026 to Bullish from 2027 onward.
Overall, the path suggests growing investor upside with rising averages into the late 2030s and beyond, though these figures are estimates and not guarantees, and actual results may vary depending on market conditions and company performance.
Tap a question to reveal the answer.
The forecast shows an average price of $678.14 in 2030 with a minimum of $522.32, a maximum of $941.31, and a ROI of 162.8%, with bullish sentiment.
The long-run forecast indicates bullish sentiment from 2027 onward, with rising averages and ROIs (e.g., 2030 avg $678.14 ROI 162.8%, 2040 avg $2,046.39 ROI 693.1%, 2050 avg $4,984.81 ROI 1831.9%), suggesting meaningful upside under the provided assumptions.
Yes. The forecast shows 2034 with an average of $1,032.75 and 2035 with an average of $1,270.42, indicating the asset could exceed $1,000 by 2035 according to the numbers.
Current price is $258.03 and market cap is $36.95B.
The 30-day range is $224.28 to $296.85, RSI is 50, SMA50 is $237.96, SMA200 is $218.32, with support at $212.07 and resistance at $283.80; the sentiment is bullish.
Natera, Inc. Community Discussion
0Share your Natera, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.